Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany

Abstract

Measurement of HbA1c is an essential laboratory measure for the follow-up and therapy decision-making in patients with diabetes. HbA1c is one of the measurands in laboratory medicine that have to be successfully checked according to the criteria of the guidelines of the German Medical Association (Rili-BAEK) in external quality assurance using the reference method value concept, when applied in patient care. The allowed deviation of ±18% in external quality assessment (EQA) and ± 10% in internal quality control has been ultimately met by virtually all the different manufacturers and methods. However, such broad limits for permissible deviations are not suitable in view of medical requirements in patient care. The low-level acceptance criteria also depends on the previously used EQA materials used in Germany. In fact, HbA1c measurement results that are imprecisely measured or come from incorrectly calibrated devices are difficult to identify. With implementation of unprocessed fresh EDTA blood, the situation has changed. Until now systems with unit use reagents for point-of-care testing (POCT) of HbA1c are not mandatory to participate in EQA schemes in Germany. This paper outlines why there was a need to narrow the acceptance limits listed within the Rili-BAEK for HbA1c’s internal (to ± 3%) and external (to ± 8%) quality controls in EQA schemes for Germany, which will take place after a transition period in the next years. Higher quality in HbA1c measurements will help to avoid misdiagnosis of diabetes as well as potential over- or undertreatment of patients at risk for diabetes.

Key words

HbA1c - quality control - external quality assessment scheme - sample material

• References

• 1 Nathan DN. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1685
• 2 Holman R. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-88
• 3 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
• 4 American Diabetes Association . Standards ofMedical Care in Diabetes - 2013. Diabetes Care 2013; 36 (Suppl. 01) S11-S66
• 5 John WG. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med 2012; 29: 1350-1357
• 6 Nauck M, Petermann A, Müller-Wieland D, Kerner W, Müller UA, Landgraf R, Freckmann G, Heinemann L. Definition, klassifikation und diagnostik des diabetes mellitus. Diabetol Stoffwech 2017; 12 (Suppl. 02) S94-S100
• 7 Kowall B, Rathmann W. HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?. Diabetes Metab Syndr Obes 2013; 6: 477-491
• 8 Kowall B, Rathmann W, Landgraf R. Is HbA1c a valid and feasible tool for the diagnosis of diabetes?. Diabetes Res Clin Pract 2011; 93: 314-316
• 9 Landgraf R, Kowall B, Rathmann W. HbA1c – ein Alleskönner?. Diabetologe 2011; 7: 335-346
• 10 Hanas R, John G. 2010; consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Clin Chem 2010: 1362-1364
• 11 The International Expert Committee . International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009; 32: 1327-1334
• 12 Bundesärztekammer . Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Dtsch Ärzteblatt 2014; 111: A1583-A1618
• 13 http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2017:117:TOC
• 14 Kaiser P, Spannagl M, van CC, Lenga Y, Siebelder C, Weykamp C. HbA1c: EQA in Germany, Belgium and the Netherlands using fresh whole blood samples with target values assigned with the IFCC reference system. Clin Chem Lab Med 2016; 54: 1769-1775
• 15 Kaiser P, Peetz D, Spannagl M. Qualitätssicherung in der diabetologie: HbA1c-Ringversuche - etabliert mit kommutablen probenmaterial. Diabetologe 2016; 12: 1-4
• 16 Rathmann W, Kowall B, Tamayo T, Giani G, Holle R, Thorand B, Heier M, Huth C, Meisinger C. Hemoglobin A1c and glucose criteria identify different subjects as having type 2 diabetes in middle-aged and older populations: The KORA S4/F4 Study. Ann Med 2012; 44: 170-177
• 17 Roth J, Muller N, Lehmann T, Boer K, Lobel S, Pum J, Muller UA. Comparison of HbA1c Measurements using 3 Methods in 75 patients referred to one outpatient department. Exp Clin Endocrinol Diabetes 2018; 126: 23-26
• 18 Müller-Wieland D, Petermann A, Nauck M, Heinemann L, Kerner W, Landgraf R. Definition, klassifikation und diagnostik des diabetes mellitus (DDG Praxisempfehlung). Diabetologie 2016; 11: S78-S81
• 19 Köbberling J, Kerlin A, Creutzfeldt W. The reproducibility of the oral glucose tolerance test over long (5 years) and short periods (1 week). Klin Wochenschr 1998; 58: 527-530
• 20 Balion CM, Raina PS, Gerstein HC, Santaguida PL, Morrison KM, Booker L, Hunt DL. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: A systematic review. Clin Chem Lab Med 2007; 45: 1180-1185
• 21 Dagogo-Jack S. Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6: 589-595
• 22 Harada K, Sumida K, Yamaguchi Y, Akai Y. Relationship between the accuracy of glycemic markers and the chronic kidney disease stage in patients with type 2 diabetes mellitus. Clin Nephrol 2014; 82: 107-114
• 23 Chen HS, Wu TE, Lin HD, Jap TS, Hsiao LC, Lee SH, Lin SH. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis 2010; 55: 867-874
• 24 Heinemann L, Deiss D, Siegmund T, Schlüter S, Naudorf M, von Sengbusch S, Lange K, Freckmann G. Glukosemessung und -kontrolle bei Patienten mit Typ-1- oder Typ-2-Diabetes (DDG Praxisempfehlung). Diabetologie und Stoffwechsel 2017; 12 (Suppl. 02) S242-S262
• 25 Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112: 4284-4291
• 26 Sayinalp S, Sozen T, Usman A, Dundar S. Investigation of the effect of poorly controlled diabetes mellitus on erythrocyte life. J Diabetes Complicat 1995; 9: 190-193
• 27 Andreis E, Appel M, Küllmer KA. Kalibrierung von Messsystemen zur Blutzuckerselbstkontrolle. Diabetes Stoffwech. Herz 2013; 22: 149-155
• 28 Sacks D, Arnold M, Bakris GL, Bruns DE, Horvarth AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34: e61-e99
• 29 Mosca A, Weykamp C. Feasibility of an EQAS for HbA1c in Italy using fresh blood samples. Clin Chem Lab Med 2014; 52: e151-e153
• 30 Lenters-Westra E, Slingerland RJ. Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria. Clin Chem 2014; 60: 1062-1072
• 31 Hirst JA, McLellan JH, Price CP, English E, Feakins BG, Stevens RJ, Farmer AJ. Performance of point-of-care HbA1c test devices: implications for use in clinical practice - a systematic review and meta-analysis. Clin Chem Lab Med 2017; 55: 167-180